14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
HQY vs TEM: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
HQY Overall Winner
6-Pillar Tally: HQY 4 – 2 TEM
Matrix Metrics: HQY 7 – 3 TEM
As of Nov 17, 2026, HealthEquity, Inc (HQY) is the stronger overall head-to-head candidate over Tempus AI, Inc. (TEM) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). HQY carries a Unified Composite Score of 41.2/100 (SELL) at $101.84 (23.0x Forward P/E, 26.1% operating margin), whereas TEM carries 43.5/100 (HOLD) at $63.43 (N/M Forward P/E, -18.5% operating margin).
Composite vs. Pillar Nuance: While TEM currently prints a higher short-term Unified Composite Score (43.5/100 HOLD vs. HQY 41.2/100 SELL), HQY captures the overall institutional head-to-head verdict (7–3 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (26.1% vs. -18.5% operating margin) and revenue trajectory (+7.6% vs. +23.1% YoY).
Technical & Structure Timing Caution: HQY trades in a Markup technical trend (CONSOLIDATION options phase, RSI 53.7); meanwhile TEM is in a Breakdown options structure phase (RSI 40.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Health Information Services value chain with $8.6B market capitalization and 26.1% operating margin.
OpEx & R&D Reinvestment45.1% of Rev ($614M)
90D Engineering Disclosures0 Published
TEM Moat ProfileEcosystem & Network-Effect Moat
Health Information Services Operator
Competes within the Health Information Services value chain with $13.1B market capitalization and -18.5% operating margin.
OpEx & R&D Reinvestment83.0% of Rev ($1.25B)
90D Engineering Disclosures0 Published · AI Drug Discovery
Investor FAQ HQY vs TEM Key Questions & Quantitative Answers
As of Nov 17, 2026, HealthEquity, Inc (HQY) is the stronger overall head-to-head candidate over Tempus AI, Inc. (TEM) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). HQY carries a Unified Composite Score of 41.2/100 (SELL) at $101.84 (23.0x Forward P/E, 26.1% operating margin), whereas TEM carries 43.5/100 (HOLD) at $63.43 (N/M Forward P/E, -18.5% operating margin). Composite vs. Pillar Nuance: While TEM currently prints a higher short-term Unified Composite Score (43.5/100 HOLD vs. HQY 41.2/100 SELL), HQY captures the overall institutional head-to-head verdict (7–3 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (26.1% vs. -18.5% operating margin) and revenue trajectory (+7.6% vs. +23.1% YoY). Technical & Structure Timing Caution: HQY trades in a Markup technical trend (CONSOLIDATION options phase, RSI 53.7); meanwhile TEM is in a Breakdown options structure phase (RSI 40.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
TEM leads the Growth & Scale pillar: HQY posts +7.6% YoY revenue growth and +14.7% YoY earnings growth on $1.36B TTM revenue (71.2% gross margin, 26.1% operating margin), compared with TEM at +23.1% YoY revenue growth and +0.0% YoY earnings growth on $1.51B TTM revenue (64.5% gross margin, -18.5% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), HQY cumulative revenue shifted +351.7% while TEM shifted +296.9%. In operating R&D and SG&A reinvestment, HQY deploys 45.1% of Rev ($614M) (0 90-day corporate R&D disclosures) versus 83.0% of Rev ($1.25B) (0 disclosures) for TEM.
HQY screens cheaper on headline valuation multiples. HQY trades at 23.0x Forward P/E, 37.4x Trailing P/E, 1.27x PEG, and 6.8x EV/Revenue (32.1% FCF margin), whereas TEM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 9.2x EV/Revenue (-10.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against HQY (11.4% ROE) versus TEM (-37.5% ROE) capital efficiency.
In options market volatility and institutional positioning, HQY carries 35.8% implied volatility (12th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.29β · 39% Vol realized risk). By comparison, TEM carries 99.3% implied volatility (44th %ile, Balanced (25th–60th %ile)), a 0.49x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.51β · 93% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.